Copyright
©The Author(s) 2020.
World J Hepatol. Oct 27, 2020; 12(10): 850-862
Published online Oct 27, 2020. doi: 10.4254/wjh.v12.i10.850
Published online Oct 27, 2020. doi: 10.4254/wjh.v12.i10.850
Table 1 Baseline laboratory and endoscopic findings of the enrolled patients
Variable | Liver cirrhosis with EVs | Liver cirrhosis without EVs | Control group | P value1 |
n | 90 | 90 | 60 | - |
Sex (M/F) | 62/28 | 60/30 | 40/20 | 0.4 |
Age (yr) | 49.6 ± 8.4 | 47.7 ± 9.7 | 46 ± 6.7 | 0.32 |
BMI (kg/m2) | 26.3 ± 2.1 | 25.8 ± 1.3 | 26.6 ± 0.9 | 0.21 |
ABI | 0.94 ± 0.09 | 1.08 ± 0.13 | 1.16 ± 0.11 | 0.001 |
AST (IU/L) | 53.7 ± 10.2 | 43.7 ± 5.6 | 31.1 ± 10.8 | 0.001 |
ALT (IU/L) | 47.2 ± 7.8 | 36.2 ± 8.5 | 30.6 ± 7.7 | 0.001 |
Platelet count × 103 | 79.2 ± 21.2 | 189.3 ± 43.2 | 197.7 ± 18.7 | 0.001 |
Total cholesterol (mg/dL) | 177.6 ± 18.8 | 199.2 ± 27.4 | 210.4 ± 12.6 | 0.01 |
HDL (mg/dL) | 39.5 ± 4.3 | 44.6 ± 7.1 | 35.4 ± 5.3 | 0.004 |
TGs (mg/dL) | 135.7 ± 14.4 | 168.8 ± 12.8 | 180.8 ± 8.4 | 0.01 |
VLDL (mg/dL) | 16.6 ± 4.3 | 26.5 ± 5.3 | 25 ± 5.7 | 0.001 |
LDL (mg/dL) | 105.8 ± 14.5 | 128.9 ± 20.6 | 138.9 ± 16.5 | 0.03 |
FIB-4 | 4.97 ± 1.8 | 1.54 ± 0.47 | 1.51 ± 0.3 | 0.001 |
Platelets/SD ratio | 449 ± 167 | 1375 ± 380 | 1702 ± 238 | 0.001 |
LDL/platelet count ratio | 1.41 ± 0.4 | 0.71 ± 0.21 | 0.75 ± 0.09 | 0.001 |
Child-Pugh class (n) | A (26), B (46), C (18) | A (88), B (2) | Non-cirrhotic | - |
Endoscopy | - | - | - | - |
EVs | - | - | - | - |
Grade I-II, n (%) | 32 (35.5) | - | - | - |
Grade III, n (%) | 42 (46.7) | - | - | - |
Grade IV, n (%) | 16 (17.8) | - | - | - |
2Fundal varix, n (%) | 12 (13.3) | - | - | - |
- Citation: Hanafy AS, Basha MAK, Wadea FM. Novel markers of endothelial dysfunction in hepatitis C virus-related cirrhosis: More than a mere prediction of esophageal varices. World J Hepatol 2020; 12(10): 850-862
- URL: https://www.wjgnet.com/1948-5182/full/v12/i10/850.htm
- DOI: https://dx.doi.org/10.4254/wjh.v12.i10.850